Ionis Pharmaceuticals, Inc.
IONS
$43.03
$0.050.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 944.05M | 717.25M | 705.14M | 803.07M | 813.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 944.05M | 717.25M | 705.14M | 803.07M | 813.46M |
| Cost of Revenue | 886.69M | 891.30M | 905.65M | 915.94M | 912.63M |
| Gross Profit | 57.37M | -174.05M | -200.51M | -112.88M | -99.17M |
| SG&A Expenses | 323.89M | 298.38M | 274.57M | 237.51M | 245.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.21B | 1.19B | 1.18B | 1.15B | 1.16B |
| Operating Income | -266.52M | -472.43M | -475.08M | -350.38M | -344.99M |
| Income Before Tax | -274.43M | -464.16M | -460.07M | -355.80M | -352.50M |
| Income Tax Expenses | -6.22M | -6.13M | -6.17M | 3.01M | 13.24M |
| Earnings from Continuing Operations | -268.22 | -458.03 | -453.90 | -358.81 | -365.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -268.22M | -458.03M | -453.90M | -358.81M | -365.74M |
| EBIT | -266.52M | -472.43M | -475.08M | -350.38M | -344.99M |
| EBITDA | -255.17M | -460.86M | -463.13M | -337.93M | -332.34M |
| EPS Basic | -1.76 | -2.99 | -3.04 | -2.44 | -2.53 |
| Normalized Basic EPS | -1.04 | -1.86 | -1.91 | -1.42 | -1.42 |
| EPS Diluted | -1.83 | -2.99 | -3.04 | -2.44 | -2.53 |
| Normalized Diluted EPS | -1.11 | -1.86 | -1.91 | -1.42 | -1.42 |
| Average Basic Shares Outstanding | 624.47M | 611.29M | 598.09M | 584.09M | 578.81M |
| Average Diluted Shares Outstanding | 647.66M | 611.29M | 598.09M | 584.09M | 578.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |